-
RTS,S was the first malaria vaccine recommended by the World Health Organization in 2021. The two companies said the price reduction is driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins
-
Study findings have been published in the Science Direct, Vaccine journal 126998 to assess a double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority and lot-to-lot consistency of single component oral cholera vaccine
-
The Biolumpivaxin will help in disease surveillance to protect livestock from Lumpy Skin disease
-
Urges youth to recognise the wealth of scientific knowledge available, embrace fundamentals of science
-
Biolumpivaxin is a single vaccination regimen given once a year to cattle and buffaloes above 3 months of age.
-
To mitigate this global shortage of oral cholera vaccine, Bharat Biotech has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses of Hillchol, a press release said
-
D. Sai Prasad, Chairman, CII Telangana & Executive Director, Bharat Biotech International, underscored the importance of the CII CFO Forum as a platform for finance professionals to exchange strategies and insights.
-
Bharat Biotech said that its Covid-19 vaccine Covaxin has an excellent safety record without any vaccine-associated incidents of blood clots, thrombocytopenia, etc.
-
Dr. Ella takes over from Adar C Poonawala, who held the post from 2019 to March 2024.
-
An agreement has been signed between Bharat Biotech International Limited (BBIL) and BBio wherein BBIL will procure drug substances for the production of OPV to be supplied within India and globally.
-
The clinical trials are being carried out by Bharat Biotech in collaboration with Biofabri, the noted vaccine developer from Spain.
-
Genome Valley: It is home to more than 200 companies with a scientific workforce of about 20,000 professionals
-
Dr Krishna M Ella released a book “Economics of Covid-19- Digital Health, Education and Psychology” at his office at Hyderabad
-
It is the world's first intranasal Covid-19 vaccine to receive approval for the primary 2-dose schedule, and as a heterologous booster dose.
-
The vaccine manufacturer had already received approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month for the nasal vaccine, the first of its kind in India.
-
NCOVACC is the world's first intranasal vaccine for COVID to receive approval for the primary two-dose schedule, and as a heterologous booster dose.
-
The availability of intranasal vaccine will strengthen the fight against the pandemic and broaden vaccine coverage.
-
Bharat Biotech on Monday announced that its iNCOVACC, its Covid vaccine in the form of nasal drops, has received approval from the CDSCO
-
New Delhi: India’s first intranasal Covid vaccine by Bharat Biotech on Tuesday got the approval from the Drug Controller General of India for 18+ age group for restricted use in emergency situation. Announcing the achievements, Union Health Minister Mansukh Mandaviya termed it a ‘big boost to India’s fight against Covid-19. “Big Boost to India’s Fight […]
-
Hyderabad: Hyderabad headquartered vaccine developer Bharat Biotech International Limited (BBIL) announced that its rotavirus oral vaccine Rotavac has been introduced by Nigeria to immunise its children from the life-threatening diarrhoeal disease. Nigeria currently accounts for 14% of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the […]
